Patents by Inventor Robert Zahler

Robert Zahler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190169181
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 6, 2019
    Inventors: Robert Zahler, James E. Vath
  • Publication number: 20190117661
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 25, 2019
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Publication number: 20190092781
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Publication number: 20190084968
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 21, 2019
    Inventors: Robert Zahler, James E. Vath
  • Publication number: 20190084969
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 21, 2019
    Inventors: Robert Zahler, James E. Vath
  • Patent number: 10220015
    Abstract: The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 5, 2019
    Assignee: Zafgen, Inc.
    Inventors: Robert Zahler, James E. Vath
  • Publication number: 20190023716
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 24, 2019
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Patent number: 10174009
    Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 8, 2019
    Assignee: Zafgen, Inc.
    Inventors: Thomas D. Pallin, Susan M. Cramp, Robert Zahler
  • Patent number: 10172864
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 10175256
    Abstract: The invention relates to compositions and methods for utilizing lysophosphatidylcholine scaffolds. The compositions and methods can be used for LPC-mediated delivery of fatty acids and other molecules; to screen and identify fatty acid formulations for parenteral nutrition; and for live animal organ imaging, among other uses. The invention also provides compositions and methods for utilizing mutations and polymorphisms in human Mfsd2a as markers for neurological deficits.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: January 8, 2019
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: David Lawrence Silver, Nam Long Nguyen, Robert Zahler
  • Publication number: 20190002398
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 3, 2019
    Inventors: Jingye Shanghai, Xiao-Yi Xiao, Louis Plamondon, Diana K. Hunt, Roger B. Clark, Robert Zahler
  • Publication number: 20180360795
    Abstract: The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Inventors: Robert Zahler, James E. Vath
  • Publication number: 20180237449
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 23, 2018
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Publication number: 20180230137
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 16, 2018
    Inventors: Robert Zahler, James E. Vath
  • Patent number: 10028961
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: July 24, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 10023561
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: July 17, 2018
    Assignee: Zafgen, Inc.
    Inventors: James E. Vath, Robert Zahler
  • Patent number: 9944613
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 17, 2018
    Assignee: Zafgen, Inc.
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Publication number: 20180079737
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 22, 2018
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Patent number: 9895339
    Abstract: The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: February 20, 2018
    Assignee: Zafgen, Inc.
    Inventors: Robert Zahler, James E. Vath
  • Patent number: 9868717
    Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 16, 2018
    Assignee: Zafgen, Inc.
    Inventors: Thomas D. Pallin, Susan M. Cramp, Hazel J. Dyke, Robert Zahler